1. Home
  2. RBKB vs CHRS Comparison

RBKB vs CHRS Comparison

Compare RBKB & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RBKB

Rhinebeck Bancorp Inc.

N/A

Current Price

$16.15

Market Cap

178.3M

Sector

Finance

ML Signal

N/A

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.67

Market Cap

186.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RBKB
CHRS
Founded
1860
2010
Country
United States
United States
Employees
168
N/A
Industry
Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
178.3M
186.0M
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
RBKB
CHRS
Price
$16.15
$1.67
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
17.7K
1.9M
Earning Date
04-27-2026
04-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
109.88
EPS
0.70
1.77
Revenue
$3,002,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$79.63
P/E Ratio
$22.87
$0.95
Revenue Growth
4.24
N/A
52 Week Low
$9.31
$0.72
52 Week High
$16.23
$2.62

Technical Indicators

Market Signals
Indicator
RBKB
CHRS
Relative Strength Index (RSI) 77.16 43.47
Support Level $11.38 $1.55
Resistance Level N/A $1.75
Average True Range (ATR) 0.62 0.11
MACD 0.14 -0.04
Stochastic Oscillator 95.86 13.71

Price Performance

Historical Comparison
RBKB
CHRS

About RBKB Rhinebeck Bancorp Inc.

Rhinebeck Bancorp Inc is the holding company for Rhinebeck Bank which provides a full range of banking and financial services to consumer and commercial customers. Financial services, including investment advisory and financial product sales, are offered through a division of the Bank doing business as Rhinebeck Asset Management (RAM). The Bank's primary business activity is accepting deposits from the general public and using those funds to originate indirect automobile loans (automobile loans referred by automobile dealerships), commercial real estate loans (which include multi-family real estate loans and commercial construction loans), commercial business loans and one-to four-family residential real estate loans, and to purchase investment securities.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: